Key Points
Most important issues of Chapter:
• There is a need to enhance translation of genetic innovations into better care;
• Building of the evidence-base for their clinical validity and utility is necessary;
• One approach to streamline this process is multidisciplinary research;
• Involvement of decision makers at all levels is necessary to accelerate uptake;
• A systematic knowledge translation strategy is also important.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
AETMIS. Le syndrome du X fragile: la place du diagnostic moléculaire et du dépistage dans une approche intégrée des services. Blancquaert, I., Caron, L., and AETMIS. 2001.
AETMIS. Le dépistage prénatal du syndrome de Down et d’autres aneuploïdies au premier trimestre de la grossesse. Framarin, A., and AETMIS. 2003.
AETMIS. Contribution des analyses moléculaires des gènes BRCA1/2 à l’évaluation du risque de prédisposition au cancer du sein ou de l’ovaire: rapport sommaire. Tranchemontagne, J., Boothroyd, L., and Blancquaert, I., and AETMIS. 2006.
AETMIS. La spectrométrie de masse en tandem et le dépistage néonatal sanguin au Québec. Makni, H., St-Hilaire, C., Robb, L., Larouche, K., and Blancquaert, I. [2007-03] – ID: 9944/9947. 2007.
Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008 April; 86(4): 317–319.
CETS. Dépistage familial et diagnostic moléculaire de la dystrophie myotonique de Steinert. Conseil d’évaluation des technologies en santé, Gouvernement du Québec. 1997a.
CETS. Dépistage familial et diagnostic moléculaire des dystrophies musculaires de Duchenne et de Becker. Conseil d’évaluation des technologies en santé, Gouvernement du Québec. 1997b.
CETS. Tyrosinémie héréditaire de type I: contribution de la génétique moléculaire au dépistage familial des porteurs. Conseil d’évaluation des technologies en santé, Gouvernement du Québec. 1998.
CETS. Les enjeux du dépistage et du diagnostic prénatal du syndrome de Down. Framarin, A., and AETMIS. Conseil d’évaluation des technologies en santé, Gouvernement du Québec 1999.
Department of Health and Human Services of USA. U.S. System of Oversight of Genetic Testing: A response to the charge of the secretary of health and human services. SACGHS Secretary’s Advisory Committee on Genetics, H., and Society. April 2008.
Gagne G, Reinharz D, Laflamme N, et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet 2007; 71: 46–58.
Gekas G, Gagné G, Bujold E, et al. Comparison of different strategies in prenatal screening for Down’s syndrome: cost effectiveness analysis of computer simulation. Br Med J 2009; 338: b138, (e-print). Will be updated with paper publication data.
Giroux S, Dube-Linteau A, Cardinal G, et al. Assessment of the prevalence of the 985A>G MCAD mutation in the French-Canadian population using allele-specific PCR. Clin Genet 2007; 71: 569–575.
Giroux S, Elfassihi L, Cardinal G, et al. LRP5 coding polymorphisms influence the variation of peak bone mass in a normal population of French-Canadian women. Bone 2007b; 40: 1299–1307.
Giroux S, Elfassihi L, Rousseau F. CYP1A1: ethnic and population differences in allelic frequencies and interpretation of bone biology studies. J Bone Miner Res 2006; 21, 1959; author reply, 1960–1961.
Gravel K, Legare F, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals’ perceptions. Implement Sci 2006; 1: 16.
INSPQ. (in revision). Rapport d’évaluation de la pertinence du dépistage néonatal de l’anémie falciforme au Québec. Laflamme, N., Lindsay, C., Gagné, G., and Fortier, M. Institut National de Santé Publique du Québec, Gouvernement du Québec 2009.
Ioannidis JP. Evolution and translation of research findings: from bench to where? PLoS Clin Trials 2006; 1: e36.
Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665–674.
Lamothe L, Reinharz D, Paquette M. La construction émergente d’un champ organisationnel: le domaine de la génétique au Québec. In CALASS Marseille. 2007.
Legare F, Moher D, Elwyn G, Leblanc A, and Gravel K. Instruments to assess the perception of physicians in the decision-making process of specific clinical encounters: a systematic review. BMC Med Inform Decis Mak 2007b; 7: 30.
Legare F, Stacey D, Forest PG. Shared decision-making in Canada: update, challenges and where next!. Z Arztl Fortbild Qualitatssich 2007c; 101: 213–221.
Légaré F, Ratté S, Stacey D, et al. Interventions for improving the adoption of shared decision making by healthcare professionals. (Protocol). Cochrane Database Syst Rev 2007; Art. No.: CD006732. DOI: 10.1002/14651858.CD006732.
Miller F, Wilson B, Grimshaw J, et al. The Helix in the labyrinth: do we need genetic health services and policy research? Healthc Policy, Healthcare Policy/Politiques de Santé, 2008; 4(1): 30–38.
O’Connor AM. Using decision aids to help patients navigate the “grey zone” of medical decision-making. CMAJ 2007; 176: 1597–1598.
OECD. Health Technologies and Decision Making. OECD, 2005.
Petit E, Tassé AM, Godard B. An empirical analysis of the legal frameworks governing genetic services labs in Canadian provinces. Health Law Rev 2008; 16: 65–72.
St-Jacques S, Grenier S, Charland M, et al. Decisional needs assessment regarding Down’s syndrome prenatal testing: A systematic review of women, their partners and health professionals’ perceptions. Prenatal Diagnosis 2008; 28(13): 1183–1203.
Tassé AM and Godard B. L’encadrement législatif de la vente directe des tests génétiques et le système de santé québécois. Health Law J 2007; 15: 441–468.
Zimmern RL and Kroase M. The evaluation of genetic tests. J Public Health (Oxf) 2007 Sep; 29(3): 246–250, Epub 2007 May 24.
Acknowledgements
Dr François Rousseau holds a Fonds de Recherche en Santé du Québec national scientist award. The CanGèneTest research consortium on genetic laboratory services is funded by the Institute of Genetics of the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Canada, the Canadian Agency for Drugs and Technologies in Health and the Canadian Genetics Diseases Network of Centres of Excellence.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Rousseau, F. (2010). The CanGèneTest Pan-Canadian Research Consortium on Genetic Laboratory Services. In: Kristoffersson, U., Schmidtke, J., Cassiman, J. (eds) Quality Issues in Clinical Genetic Services. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3919-4_2
Download citation
DOI: https://doi.org/10.1007/978-90-481-3919-4_2
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3918-7
Online ISBN: 978-90-481-3919-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)